(A) Individual coefficient of risk for high-risk FLIPI; ECOG performance status; and mutations in EP300, FOX01, CREBBP, CARD11, MEF2B, ARID1A, and EZH2. Mutations in MEF2B, ARID1A, and EZH2 are all “favorable” findings. (B) Mutational frequency of the various genes in the training set and in the validation cohort. (C) Failure-free survival by FLIPI risk and by m7-FLIPI risk in the training cohort. (D) Failure-free survival by FLIPI risk and by m7-FLIPI risk in the validation cohort.